Background: Pantoprazole is a proton pump inhibitor drug mainly used for treating peptic diseases. Adverse effects of pantoprazole in the occasional central nervous system (CNS) include headache, vertigo and sleep disturbances. Data in rats suggest that proton pumps are expressed in the inner ear and in the epithelium of the choroid plexus, which would be a potential target to mediate such proton pump inhibitor effects. Methods: To assess the distribution of pantoprazole into the human CNS despite its low lipophilicity (log p = 0.5), we quantified pantoprazole concentrations by liquid chromatography/tandem mass spectrometry in serum and cerebrospinal fluid retain samples withdrawn simultaneously. Twenty-six sample pairs were obtained from 23 neurological patients with therapeutic administration of pantoprazole prior to sampling. Results: Median (interquartile range) serum concentration of total pantoprazole was 142 ng/ml (30.8-622). Cerebrospinal fluid concentration of total pantoprazole was 2.79 ng/ml (1.59-7.3) and reached 2.0% (1.0-4.5%) of simultaneous serum concentrations. Conclusion: This value corresponds to the unbound fraction of pantoprazole in serum reported previously and indicates that pantoprazole CNS concentrations are high enough to exert some effects on possible CNS targets.

Moreira Dias L: Pantoprazole: a proton pump inhibitor. Clin Drug Investig 2009;29(suppl 2):3-12.
Beil W, Sewing KF, Kromer W: Basic aspects of selectivity of pantoprazole and its pharmacological actions. Drugs Today (Barc) 1999;35:753-764.
Lecain E, et al: Gastric proton pump is expressed in the inner ear and choroid plexus of the rat. Hear Res 2000;149:147-154.
SPC: Pantoprazole 20 mg Gastro-Resistant Tablets, 2016.
Huber R, et al: Pharmacokinetics of pantoprazole in man. Int J Clin Pharmacol Ther 1996;34:185-194.
Dawidowicz AL, Kalitynski R, Fijalkowska A: Free and bound propofol concentrations in human cerebrospinal fluid. Br J Clin Pharmacol 2003;56:545-550.
Wu D, et al: Systematic toxicity mechanism analysis of proton pump inhibitors: an in silico study. Chem Res Toxicol 2015;28:419-430.
Fallahzadeh MK, Borhani Haghighi A, Namazi MR: Proton pump inhibitors: predisposers to Alzheimer disease? J Clin Pharm Ther 2010;35:125-126.
Badiola N, et al: The proton-pump inhibitor lansoprazole enhances amyloid beta production. PLoS One 2013;8:e58837.
Gomm W, et al: Association of proton pump inhibitors with risk of dementia: a pharmacoepidemiological claims data analysis. JAMA Neurol 2016, Epub ahead of print.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.